

Ascendiant Capital Markets LLC serves as Financial Advisor on Biolase, Inc's \$8,500,000 Public Offering and Concurrent Private Placement

IRVINE, Calif., October 30, 2019 -- Ascendiant Capital Markets LLC ("Ascendiant") announced today the closing of a \$8,500,000 Public Offering and concurrent Private Placement for Biolase, Inc. (NasdaqCM: BIOL) of Irvine, California.

Ascendiant served as a Financial Advisor on the transaction.

Biolase intends to use the proceeds for working capital, including new product development, launch and subsequent scale-ups, as well as other general corporate purposes.

About Biolase, Inc.

Biolase Inc. (NasdaqCM: BIOL) is a medical device company that is a global market leader in the manufacturing and marketing of proprietary dental laser systems that enable dentists and dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and surgical applications. BIOLASE's laser systems are designed to provide clinically superior, patient-friendly results for many types of common dental procedures compared to those achieved with traditional instruments. BIOLASE has sold 38,900 laser systems to date in over 90 countries around the world. For more information, visit www.biolase.com

About Ascendiant Capital Markets LLC

Ascendiant Capital Markets, LLC, based in Irvine, California, is a full-service investment banking, equity research, market making, and securities trading firm focused on public and private companies, and institutional, accredited, and strategic investors.

Ascendiant has led or participated in over \$1 billion in financing transactions, and the members of Ascendiant's Investment Banking Team have completed over 300 M&A transactions.

Ascendiant Capital Markets is registered with the United States Securities and Exchange Commission (SEC) as a broker-dealer, and is a member of the FINRA and SIPC.

For more information, please visit www.ascendiant.com or contact Bradley J. Wilhite, Co-Founder & Managing Partner, at 949.259.4949 or bwilhite@ascendiant.com

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.